3,6-dichloropyrazine-2-carbonitrile
July 3, 2020
Favipiravir(259793-96-9)
Favipiravir, also called T 705,which is a pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host enzymes and selectively inhibits the influenza viral RNA-dependent RNA polymerase.On the base of Favipiravir mechanism, It often treat influenza in Japan and it was also being studied to treat a number of other viral infections.Especially for coronavirus(COVID-2019), Favipiravir was approved for treatment of COVID-2019 by China, Japan, Russia,Korea, India…. After several clinical trials at different countries, this drug has shown very positive results.
Favipiravir(259793-96-9) Information
| Product | Favipiravir | ||
| CAS No. | 259793-96-9 | ||
| Synonyms | T705
6-fluoro-3-hydroxypyrazine-2-carboxamide 6-fluoro-3-hydroxy-2-carboxamide |
||
| Availability | In Stock | ||
| MF. | C5H4FN3O2 | MW. | 157.1025632 |
| Appearance | Yellowish to off – white crystalline powder | Purity | 98% |
| Application |
For research use only |
Storage | RT |
| COA & NMR | Download | MSDS | Download |
[Reference]
[1] Koons C (7 August 2014). “Ebola Drug From Japan May Emerge Among Key Candidates”. Bloomberg.com.
[2] Fink S (4 February 2015). “Ebola Drug Aids Some in a Study in West Africa”. The New York Times.
[3] Lumby, Casper (3 March 2020). “Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child”. Clinical Infectious Diseases. Retrieved 5 May 2020.
[4] EJ Lane (June 22, 2016). “Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals”. Fierce Pharma. Retrieved April 20, 2020.
[5]”Medicine registration license ЛП-006225″. Government registry of medicines. Russian Ministry of Health. Retrieved May 30, 2020.
[6] Favipiravir
